Log In
Print this Print this

APD209 (formerly ACA1209)

  Manage Alerts
Collapse Summary General Information
Company Acacia Pharma Group plc
DescriptionOral fixed-dose combination of a progestin and a selective ADRB2 agonist
Molecular Target Adrenergic receptor beta 2 (ADRB2)
Mechanism of ActionAdrenergic receptor beta 2 (ADRB2) agonist
Therapeutic ModalitySmall molecule: Combination
Latest Stage of DevelopmentPhase II
Standard IndicationCachexia
Indication DetailsTreat cancer cachexia
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today